Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis?

Arthritis Care and Research

Volumn 65, Issue 8, 2013, Pages 1375-1380

  Liu, Xiaochun ^a   Mayes, Maureen D ^a   Pedroza, Claudia ^a   Draeger, Hilda T ^b   Gonzalez, Emilio B ^c   Harper, Brock E ^c   Reveille, John D ^a   Assassi, Shervin ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CENTROMERE ANTIBODY; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; ETHNICITY; FEMALE; FORCED VITAL CAPACITY; HUMAN; INTERSTITIAL LUNG DISEASE; LONG TERM CARE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; SEX DIFFERENCE; SMOKING; SURVIVAL; SYSTEMIC SCLEROSIS; THORAX RADIOGRAPHY;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SURVIVAL; UNITED STATES; VITAL CAPACITY;

EID: 84881361943     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21968     Document Type: Article

References (16)

1. Elhai M, Meune C, Avouac J, Kahan A, Allanore Y,. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2012; 51: 1017-26.
2. Steen VD, Conte C, Owens GR, Medsger TA Jr,. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37: 1283-9.
3. Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-15.
4. Assassi S, Sharif R, Lasky RE, McNearney TA, Estrada YM, Draeger HT, et al. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther 2010; 12: R166.
5. Furst D, Khanna D, Matucci-Cerinic M, Clements P, Steen V, Pope J, et al. Systemic sclerosis: continuing progress in developing clinical measures of response. J Rheumatol 2007; 34: 1194-200.
6. Khanna D, Tseng CH, Farmani N, Steen V, Furst DE, Clements PJ, et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum 2011; 63: 3078-85.
7. Muangchan C, Harding S, Khimdas S, Bonner A, Canadian Scleroderma Research Group, Baron M, et al. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group. Arthritis Care Res (Hoboken) 2012; 64: 1405-14.
8. Ohtsuka T,. Relation between elevated high-sensitivity C-reactive protein and anti-mitochondria antibody in patients with systemic sclerosis. J Dermatol 2008; 35: 70-5.
9. Nagy Z, Czirjak L,. Increased levels of amino terminal propeptide of type III procollagen are an unfavourable predictor of survival in systemic sclerosis. Clin Exp Rheumatol 2005; 23: 165-72.
10. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
11. Gourh P, Arnett FC, Assassi S, Tan FK, Huang M, Diekman L, et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther 2009; 11: R147.
12. Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999; 26: 2159-67.
13. Rizopoulos D,. An R package for the joint modelling of longitudinal and time-to-event data. J Stat Soft 2010; 35: 1-33.
14. Steele R, Hudson M, Lo E, Baron M, Canadian Scleroderma Research Group. Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res (Hoboken) 2012; 64: 519-24.
15. Mortensen RF,. C-reactive protein, inflammation, and innate immunity. Immunol Res 2001; 24: 163-76.
16. Ohtsuka T,. Serum interleukin-6 level is reflected in elevated high-sensitivity C-reactive protein level in patients with systemic sclerosis. J Dermatol 2010; 37: 801-6.